We are delighted to announce that Pauli Wong, Partner at Eagle IP, has been invited to speak at the Entrepreneurship Series 2026, organized by the Hong Kong Life Sciences Society (HKLSS).

Pauli will lead an essential session titled "Protecting Innovation through IP and Legal Strategy," tailored specifically for the next generation of life sciences entrepreneurs, researchers, and biotech professionals. In an industry where intellectual property is often the most valuable asset a company owns, this seminar aims to equip participants with the strategic mindset needed to safeguard their scientific breakthroughs.

At Eagle IP, we are committed to empowering the local life sciences ecosystem. We are proud to partner with HKLSS in their mission to nurture talent and bridge the gap between academic excellence and commercial success in the life sciences sector.

Our Past Events

Pauli Wong gave a talk at Hong Kong Life Sciences Society (HKLSS)

10 October 2026

BioHK2026 | Biotech IP in practice

16 September 2026

Jennifer Che Once Again Named to the IAM Strategy 300

21 August 2026

Yolanda Wang attended the 1st China Pharmaceutical Innovation Conference

22 July 2026

Pauli Wong as a Guest speaker for “Entrepreneurial Workshop” in Poly U

16 June 2026

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2026 Patent Firms Ranking List

5 June 2026

Recommended Insights

China Releases Draft Implementation Guidelines for the Drug Administration Law

2 June 2022
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]
Read more >

Can Post Filing Data Overcome Inventive Step in China?

19 November 2018
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]
Read more >

China Hands Down First Batch of Patent Linkage “Paragraph IV” Litigation Results

30 June 2022
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]
Read more >

CHINA: New Patent Examination Guidelines Now Available for Public Comment

4 August 2021
Two months after the new Chinese Patent law came into effect, the CNIPA has released a new set of Patent Examination Guidelines (proposed version) for public comments on Aug 3, 2021. Here are the explanation of the amendments (Chinese only). Here is the full set of proposed amendments (Chinese only). Briefly, the new amendment focuses […]
Read more >
Top crossarrow-right